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Abstract 3978 
Multiple myeloma (MM) is characterized by a severe unbalanced and uncoupling 
bone remodeling leading to osteolysis. We have recently shown that osteocytes are 
involved in MM-induced osteolysis through an increased cell death. Accordingly 
MM patients are characterized by a reduced number of viable osteocytes related to 
the presence of bone lesions. Proteasome inhibitors currently used in the treatment 
of MM are able to stimulate osteoblast formation but their potential effects on 
osteocyte death are not known and have been investigated in this study both in 
vitro and in vivo. 
Osteocytic MLO-Y4 cells or human pre-osteocytic HOB-01 cells were co-cultured for 
48 hours in the presence or absence of the human myeloma cell lines (HMCLs) JJN3 or 
RPMI-8226 placed in a transwell insert. A significantly reduction of ostecyte viability 
was observed (median percent reduction of MLO-Y4 viability: -16% and -30%, 
respectively). The treatment for 12–24 hours with Bortezomib (BOR) (2nM) or other 
proteasome inhibitors such as MG262 (10nM) or MG132 (100nM) significantly blunted 
MLO-Y4 and HOB-01 cell death. Similarly, Dexamethasone (DEX)-induced MLO-Y4 
apoptosis, obtained at pharmacological doses (10–4–10–5 M), was significantly reduced 
by the treatment with proteasome inhibitors. To translate our in vitro data into a clinical 
perspective we performed a retrospective histological evaluation on bone biopsies of a 
cohort of 40 newly diagnosis MM patients (24 male and 16 female, median age: 68 
years) 34 of them with symptomatic MM and 6 with smoldering MM (SMM). The 58% 
of patients with symptomatic MM have evidence of osteolytic lesions at the X-rays 
survey. Bone biopsies were obtained in both symptomatic MM and SMM at diagnosis 




























68% of patients with symptomatic MM were treated with a BOR-based regimen while 
42% do not. Moreover the 58% of MM patients received DEX and the 59% Thalidomide 
(TAL). Zoledronic acid (ZOL) was infused monthly in the 60% of MM patients. 
Osteocyte viability was evaluated in a total of 500 lacunae per histological sections, 
corresponds to the total number of osteocyte lacunae in the bone biopsies. The number 
of viable osteocytes and the number of degenerated or apoptotic osteocytes and empty 
lacunae have been evaluated. In patients with SMM no significant change was observed 
in the number of viable osteocytes in the two histological evaluations carried out 
(median percent change: +1.2, p=0.68, NS). In symptomatic MM patients the mean 
percent change of the osteocyte viability was not correlated with the response rate to 
treatment (R2 0.01, p=NS). A significant increase of the number of viable osteocytes was 
demonstrated in MM patients treated with BOR-based regimen as compared to those 
treated without BOR (% median increase of osteocyte viability: +6% vs. +1.30%, Mann-
Whitney test: p=0.017). Patients treated with BOR alone showed the highest increase of 
osteocyte viability that was statistical significant in comparison with that observed either 
in patients treated without BOR (+11.6% vs. +1.3%, p=0.0019) or in those treated with 
BOR plus DEX (+11.6% vs. +4.4%, p=0.01). On the contrary, no significant difference 
was observed in patients treated with TAL than in those treated without TAL (p= 0.7, 
NS) as well as patients treated with ZOL compared to those untreated showed no 
significant difference in the number of viable osteocytes (p=0.18, NS). To confirm the 
role of the different drug treatment on the osteocyte viability we perform a multiple 
regression non-parametric analysis showing that BOR had a significant positive impact 
on osteocyte viability (p=0.042) whereas ZOL and TAL have not (p>0.2,NS) and it 
counterbalanced the negative effect of DEX treatment (p=0.035). 
In conclusion our in vitro and in vivo data suggest the proteasome inhibitors block 
osteocyte death induced by MM cells could have a positive impact on bone integrity in 
MM patients. 
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